Hit enter to search or ESC to close
Company
Science
Pipeline
Newsroom
Investors
Careers
Contact
Overview
News Releases
Events
Stock Information
Quote
Interactive Chart
Corporate Governance
Documents & Charters
Board Committees
Financial Information
Snapshot
SEC Filings
Analyst Coverage
Key Ratios
Investor Resources
Contact IR
FAQs
Investor Alerts
RSS
Investors Menu
Overview
News Releases
Events
Stock Information
Quote
Interactive Chart
Corporate Governance
Documents & Charters
Board Committees
Financial Information
Snapshot
SEC Filings
Analyst Coverage
Key Ratios
Investor Resources
Contact IR
FAQs
Investor Alerts
RSS
News Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Investor Alerts
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Apr 23, 2023
IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma
Apr 19, 2023
IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors
Apr 3, 2023
IDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event
Mar 31, 2023
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mar 14, 2023
IDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First-in-Class Synthetic Lethality Programs IDE397 (MAT2A), IDE161 (PARG) and Werner Helicase
Mar 7, 2023
IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update
Mar 1, 2023
IDEAYA Biosciences to Participate in Investor Conferences in March 2023
Feb 16, 2023
IDEAYA Biosciences to Participate in Citi's 2023 Virtual Oncology Leadership Summit
Feb 1, 2023
IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference
Jan 23, 2023
IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
15
»
Company
Science
Pipeline
Newsroom
Investors
Careers
Contact